Sunho Biologics, Inc. (SUNHO BIO-B) disclosed a new postponement in releasing its audited financial results for the year ended 31 December 2025. The company now concedes it will miss the previously targeted 30 April 2026 deadline because its auditor has not finished the outstanding work on the 2025 annual audit.

The continued delay also means the 2025 Annual Report will not be dispatched by the 30 April 2026 cut-off stipulated under Listing Rule 13.46(2)(a). Sunho Biologics said it will issue further announcements to update shareholders on both the audit status and the revised timetable for publishing the annual results and despatching the report.

Trading in SUNHO BIO-B shares has been suspended since 9:00 a.m. on 1 April 2026 and will remain halted until the 2025 results are released. The company advises shareholders and potential investors to exercise caution when dealing in its securities.

The board currently comprises two executive directors (Mr. Zhang Feng and Ms. Jiang Xiaoling), one non-executive director (Mr. Fan Rongkui) and three independent non-executive directors (Mr. Chan Heung Wing Anthony, Ms. Feng Lan and Mr. Shi Luwen).